FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770680612> ?p ?o ?g. }

• W2770680612 endingPage "1201" @default.
• W2770680612 startingPage "1192" @default.
• W2770680612 abstract "In Brief OBJECTIVE: To evaluate whether psychostimulants used to treat attention-deficit/hyperactivity disorder (ADHD) are associated with risk of adverse placental-associated pregnancy outcomes including preeclampsia, placental abruption, growth restriction, and preterm birth. METHODS: We designed a population-based cohort study in which we examined a cohort of pregnant women and their liveborn neonates enrolled in Medicaid from 2000 to 2010. Women who received amphetamine–dextroamphetamine or methylphenidate monotherapy in the first half of pregnancy were compared with unexposed women. We considered atomoxetine, a nonstimulant ADHD medication, as a negative control exposure. To assess whether the risk period extended to the latter half of pregnancy, women who continued stimulant monotherapy after 20 weeks of gestation were compared with those who discontinued. Risk ratios and 95% CIs were estimated with propensity score stratification to control for confounders. RESULTS: Pregnancies exposed to amphetamine–dextroamphetamine (n=3,331), methylphenidate (n=1,515), and atomoxetine (n=453) monotherapy in early pregnancy were compared with 1,461,493 unexposed pregnancies. Among unexposed women, the risks of the outcomes were 3.7% for preeclampsia, 1.4% for placental abruption, 2.9% for small for gestational age, and 11.2% for preterm birth. The adjusted risk ratio for stimulant use was 1.29 for preeclampsia (95% CI 1.11–1.49), 1.13 for placental abruption (0.88–1.44), 0.91 for small for gestational age (0.77–1.07), and 1.06 for preterm birth (0.97–1.16). Compared with discontinuation (n=3,527), the adjusted risk ratio for continuation of stimulant use in the latter half of pregnancy (n=1,319) was 1.26 for preeclampsia (0.94–1.67), 1.08 for placental abruption (0.67–1.74), 1.37 for small for gestational age (0.97–1.93), and 1.30 for preterm birth (1.10–1.55). Atomoxetine was not associated with the outcomes studied. CONCLUSION: Psychostimulant use during pregnancy was associated with a small increased relative risk of preeclampsia and preterm birth. The absolute increases in risks are small and, thus, women with significant ADHD should not be counseled to suspend their ADHD treatment based on these findings. Psychostimulant use in pregnancy is associated with a small increased risk of preeclampsia and preterm birth." @default.
• W2770680612 created "2017-12-04" @default.
• W2770680612 creator A5006217491 @default.
• W2770680612 creator A5009688412 @default.
• W2770680612 creator A5024775911 @default.
• W2770680612 creator A5034554999 @default.
• W2770680612 creator A5044474781 @default.
• W2770680612 creator A5048998630 @default.
• W2770680612 creator A5055790388 @default.
• W2770680612 creator A5061744288 @default.
• W2770680612 creator A5075944192 @default.
• W2770680612 date "2017-12-01" @default.
• W2770680612 modified "2023-09-29" @default.
• W2770680612 title "Placental Complications Associated With Psychostimulant Use in Pregnancy" @default.
• W2770680612 cites W1567806054 @default.
• W2770680612 cites W1584004224 @default.
• W2770680612 cites W1900651926 @default.
• W2770680612 cites W1937522003 @default.
• W2770680612 cites W1966526645 @default.
• W2770680612 cites W2003924756 @default.
• W2770680612 cites W2004213018 @default.
• W2770680612 cites W2007231330 @default.
• W2770680612 cites W2013550669 @default.
• W2770680612 cites W2024318079 @default.
• W2770680612 cites W2040613067 @default.
• W2770680612 cites W2051493707 @default.
• W2770680612 cites W2057760214 @default.
• W2770680612 cites W2067301295 @default.
• W2770680612 cites W2078418052 @default.
• W2770680612 cites W2079389421 @default.
• W2770680612 cites W2104144931 @default.
• W2770680612 cites W2112237045 @default.
• W2770680612 cites W2162012775 @default.
• W2770680612 cites W2168728317 @default.
• W2770680612 cites W2346040249 @default.
• W2770680612 cites W2512939136 @default.
• W2770680612 cites W2530852902 @default.
• W2770680612 cites W2559506670 @default.
• W2770680612 cites W2560010172 @default.
• W2770680612 cites W2621713722 @default.
• W2770680612 cites W2622412817 @default.
• W2770680612 doi "https://doi.org/10.1097/aog.0000000000002362" @default.
• W2770680612 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5709205" @default.
• W2770680612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29112657" @default.
• W2770680612 hasPublicationYear "2017" @default.
• W2770680612 type Work @default.
• W2770680612 sameAs 2770680612 @default.
• W2770680612 citedByCount "47" @default.
• W2770680612 countsByYear W27706806122017 @default.
• W2770680612 countsByYear W27706806122018 @default.
• W2770680612 countsByYear W27706806122019 @default.
• W2770680612 countsByYear W27706806122020 @default.
• W2770680612 countsByYear W27706806122021 @default.
• W2770680612 countsByYear W27706806122022 @default.
• W2770680612 countsByYear W27706806122023 @default.
• W2770680612 crossrefType "journal-article" @default.
• W2770680612 hasAuthorship W2770680612A5006217491 @default.
• W2770680612 hasAuthorship W2770680612A5009688412 @default.
• W2770680612 hasAuthorship W2770680612A5024775911 @default.
• W2770680612 hasAuthorship W2770680612A5034554999 @default.
• W2770680612 hasAuthorship W2770680612A5044474781 @default.
• W2770680612 hasAuthorship W2770680612A5048998630 @default.
• W2770680612 hasAuthorship W2770680612A5055790388 @default.
• W2770680612 hasAuthorship W2770680612A5061744288 @default.
• W2770680612 hasAuthorship W2770680612A5075944192 @default.
• W2770680612 hasBestOaLocation W27706806122 @default.
• W2770680612 hasConcept C118552586 @default.
• W2770680612 hasConcept C126322002 @default.
• W2770680612 hasConcept C131872663 @default.
• W2770680612 hasConcept C201903717 @default.
• W2770680612 hasConcept C2776145449 @default.
• W2770680612 hasConcept C2777112843 @default.
• W2770680612 hasConcept C2777193897 @default.
• W2770680612 hasConcept C2777218350 @default.
• W2770680612 hasConcept C2779225303 @default.
• W2770680612 hasConcept C2779234561 @default.
• W2770680612 hasConcept C2780783007 @default.
• W2770680612 hasConcept C2780938740 @default.
• W2770680612 hasConcept C2908647359 @default.
• W2770680612 hasConcept C29456083 @default.
• W2770680612 hasConcept C46973012 @default.
• W2770680612 hasConcept C513476851 @default.
• W2770680612 hasConcept C54355233 @default.
• W2770680612 hasConcept C71924100 @default.
• W2770680612 hasConcept C86803240 @default.
• W2770680612 hasConcept C99454951 @default.
• W2770680612 hasConceptScore W2770680612C118552586 @default.
• W2770680612 hasConceptScore W2770680612C126322002 @default.
• W2770680612 hasConceptScore W2770680612C131872663 @default.
• W2770680612 hasConceptScore W2770680612C201903717 @default.
• W2770680612 hasConceptScore W2770680612C2776145449 @default.
• W2770680612 hasConceptScore W2770680612C2777112843 @default.
• W2770680612 hasConceptScore W2770680612C2777193897 @default.
• W2770680612 hasConceptScore W2770680612C2777218350 @default.
• W2770680612 hasConceptScore W2770680612C2779225303 @default.
• W2770680612 hasConceptScore W2770680612C2779234561 @default.
• W2770680612 hasConceptScore W2770680612C2780783007 @default.
• W2770680612 hasConceptScore W2770680612C2780938740 @default.

• next